E Lengfelder1, R Hehlmann. Show Affiliations » 1. III. Medizinische Universitätsklinik Mannheim.
Abstract
Entities: Disease
Mesh： See more » AdultAgedAntineoplastic Agents/therapeutic useAntineoplastic Agents, Alkylating/therapeutic useBloodlettingClinical Trials as TopicFibrinolytic Agents/administration & dosageFibrinolytic Agents/therapeutic useHumansHydroxyurea/therapeutic useInterferon-alpha/therapeutic useLeukemia/etiologyMiddle AgedPhlebotomyPipobroman/therapeutic usePlatelet Aggregation Inhibitors/therapeutic usePolycythemia Vera/complicationsPolycythemia Vera/mortalityPolycythemia Vera/therapyPrognosisProspective StudiesQuinazolines/administration & dosageQuinazolines/therapeutic useRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsThromboembolism/prevention & control
Substances： See more » Antineoplastic AgentsAntineoplastic Agents, AlkylatingFibrinolytic AgentsInterferon-alphaPlatelet Aggregation InhibitorsQuinazolinesPipobromananagrelideHydroxyurea
Year: 2000 PMID： 11076265 DOI： 10.1055/s-2000-7728
Source DB: PubMed Journal: Dtsch Med Wochenschr ISSN： 0012-0472 Impact factor: 0.628